Biden
inks $137 million contract to boost supply of key material for COVID
tests -source
Send a link to a friend
[December 30, 2021]
WASHINGTON (Reuters) - The Biden
administration plans to announce on Wednesday a $137 million contract
for Millipore Sigma, a unit of Germany's Merck KGaA, to boost production
capacity of a highly constrained component of rapid coronavirus tests, a
senior administration official told Reuters.
|
The money will allow the company over three years to build a new
facility to produce nitrocellulose membranes, the paper that
displays test results, in Sheboygan, Wisconsin. That, in turn, will
allow for 85 million more tests to be produced per month, the
official said.
It was not immediately clear when the facility would ramp up to full
production.
"It's probably the most constrained piece of technology in expanding
capacity, in making more of these over-the-counter or point-of-care
tests," the official said. "This amount they're going to produce is
roughly equivalent to another billion over-the-counter tests being
able to be made," he added.
Millipore Sigma is a supplier to major U.S. COVID-19 antigen test
manufacturers, he said, without providing further details.
The contract, which will be announced by the Department of Defense
for the Department of Health and Human Services, is part of a bid by
the Biden administration to ramp up production of scarce rapid
COVID-19 tests, which has taken on more urgency as nations grapple
with the highly infectious Omicron variant of the coronavirus.
The average number of daily COVID-19 cases in the United States has
hit a record high of 258,312 over the past seven days, according to
a Reuters tally.
[to top of second column] |
Earlier this month, President
Joe Biden announced a plan to distribute 500
million at-home coronavirus test kits to help
address the crisis, building on prior pledges to
invest $3 billion in test kits.
But U.S. testing is behind the curve because of a
lack of skilled workers, a shortage of at-home tests and
under-investment in recent months, and health experts in the U.S.
said Biden's latest plan was "too little, too late."
The government is invoking the Defense Production Act (DPA) to award
the contract and has many more similar contracts in the works, the
official said.
The Biden administration has used the DPA - a 1950s Korean war-era
law which gives federal agencies the power to prioritize procurement
orders related to national defense - to speed production of swabs
and pipettes for COVID-19 test production previously.
(Reporting by Alexandra Alper; Additional Reporting by Carl
O'Donnell; Editing by Chris Reese)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |